WEREWOLF THERAPEUTICS, INC. Interest Expense
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Interest Expense of $1.00 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-03.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-05-03
- WEREWOLF THERAPEUTICS, INC. interest expense for the quarter ending 2024-03-31 was $1.00M, a 483.14% increase year-over-year.
- WEREWOLF THERAPEUTICS, INC. interest expense for the quarter ending 2023-03-31 was $172.00K.
- WEREWOLF THERAPEUTICS, INC. interest expense for fiscal 2023 was $3.14M.
- WEREWOLF THERAPEUTICS, INC. interest expense for fiscal 2022 was $0.00.
| Period end | Interest Expense 3 month | Interest Expense 12 month |
|---|---|---|
| 2024-03-31 | $1.00M 10-Q · filed 2024-05-03 | |
| 2023-12-31 | $3.14M 10-K · filed 2024-03-07 | |
| 2023-03-31 | $172.00K 10-Q · filed 2024-05-03 | |
| 2022-12-31 | $0.00 10-K · filed 2024-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |